Our lab is a translational
research lab. One of our main strength is the tight collaboration with the physicians
from the Hematology Division at the Davidoff Cancer Center. Our primary field of interest is finding novel or better therapies for
the treatment of incurable hematological malignancies. Our projects focus on
understanding the effect of new agents on different leukemias and lymphomas and
on exploring the deleterious side effects caused by customary agents used
today. In addition, we are studying the molecular pathways involved in the
initiation and maintenance of hematological tumorigenesis and are trying to understand
the effect of the different agents on these molecular pathways. We use a
variety of advanced molecular and cellular techniques utilizing in-vitro,
patient derived ex-vivo and in-vivo models. Our ultimate goal is
to translate our research data and results into improved, more advanced therapeutic
options for hematological malignancy patients
1. Pathogenesis of tyrosine kinase
inhibitor (TKI) associated vascular disease in chronic myelocytic leukemia
2. NETosis in CML and the effect of
tyrosine kinase inhibitors (TKIs) on NETosis.
3. Utilizing exosomes to target
specific hematological malignany cells.
4. Mechanism of the anti-tumoral
activity of deferasirox on mantle cell lymphoma.